Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 3
2013 3
2014 4
2016 3
2017 3
2018 1
2019 4
2020 2
2021 6
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean michael a weisz[Author] (2 results)?
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. Among authors: weiss ms. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Fox E, Lovett-Racke AE, Gormley M, Liu Y, Petracca M, Cocozza S, Shubin R, Wray S, Weiss MS, Bosco JA, Power SA, Mok K, Inglese M. Fox E, et al. Among authors: weiss ms. Mult Scler. 2021 Mar;27(3):420-429. doi: 10.1177/1352458520918375. Epub 2020 Apr 30. Mult Scler. 2021. PMID: 32351164 Free PMC article. Clinical Trial.
Diagnostic Tests for Low Back Disorders.
Hegmann KT, Travis R, Belcourt RM, Donelson R, Eskay-Auerbach M, Galper J, Haldeman S, Hooper PD, Lessenger JE, Mayer T, Mueller KL, Murphy DR, Tellin WG, Thiese MS, Weiss MS. Hegmann KT, et al. Among authors: weiss ms. J Occup Environ Med. 2019 Apr;61(4):e155-e168. doi: 10.1097/JOM.0000000000001551. J Occup Environ Med. 2019. PMID: 30694882
Reply to Sayeed et al.
Travis R, Andersson GBJ, Belcourt RM, Carragee EJ, Eskay-Auerbach M, Goertz M, Haldeman S, Hegmann KT, Lessenger JE, Mayer T, Mueller KL, Murphy DR, Tellin WG, Thiese MS, Weiss MS, Harris JS. Travis R, et al. Among authors: weiss ms. J Occup Environ Med. 2022 Feb 1;64(2):e84-e86. doi: 10.1097/JOM.0000000000002453. J Occup Environ Med. 2022. PMID: 34873136 No abstract available.
Invasive Treatments for Low Back Disorders.
Hegmann KT, Travis R, Andersson GBJ, Belcourt RM, Carragee EJ, Eskay-Auerbach M, Galper J, Goertz M, Haldeman S, Hooper PD, Lessenger JE, Mayer T, Mueller KL, Murphy DR, Tellin WG, Thiese MS, Weiss MS, Harris JS. Hegmann KT, et al. Among authors: weiss ms. J Occup Environ Med. 2021 Apr 1;63(4):e215-e241. doi: 10.1097/JOM.0000000000001983. J Occup Environ Med. 2021. PMID: 33769405
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM. Wallace DS, et al. Among authors: weiss ms. Leuk Lymphoma. 2023 Sep;64(9):1579-1582. doi: 10.1080/10428194.2023.2223743. Epub 2023 Jun 21. Leuk Lymphoma. 2023. PMID: 37341984 Clinical Trial. No abstract available.
Opioids and safety-sensitive work.
Hegmann KT, Weiss MS, Bowden K, Branco F, DuBrueler K, Els C, Harris JS, Mandel S, McKinney DW, Miguel R, Mueller KL, Nadig RJ, Schaffer MI, Studt L, Talmage JB, Travis RL, Winters T, Thiese MS, Ott U. Hegmann KT, et al. Among authors: weiss ms. J Occup Environ Med. 2014 Nov;56(11):e134-5. doi: 10.1097/JOM.0000000000000341. J Occup Environ Med. 2014. PMID: 25376423 No abstract available.
Reply to Sayeed et al's Reply to Reply.
Carragee EJ, Andersson GBJ, Belcourt RM, Eskay-Auerbach M, Goertz M, Haldeman S, Hegmann KT, Lessenger JE, Mayer T, Mueller KL, Murphy DR, Tellin WG, Thiese MS, Travis R, Weiss MS, Harris JS. Carragee EJ, et al. Among authors: weiss ms. J Occup Environ Med. 2022 Jun 1;64(6):e391-e392. doi: 10.1097/JOM.0000000000002548. J Occup Environ Med. 2022. PMID: 35761429 No abstract available.
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani A, Winter A, Winter J, Gordan L, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. Hill BT, et al. Among authors: weiss ms. Blood Adv. 2024 Jan 23;8(2):378-387. doi: 10.1182/bloodadvances.2023010693. Blood Adv. 2024. PMID: 37871300 Free PMC article.
32 results